 [
    {
        "id": 8934,
        "drug_name": "TLANDO (testosterone undecanoate)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Testosterone replacement therapy (TRT)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ATRS\/news\/74522",
        "note": "Approved March 29, 2022. ",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8934,
        "drug_name": "TLANDO (testosterone undecanoate)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Testosterone replacement therapy (TRT)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ATRS\/news\/74522",
        "note": "Approved March 29, 2022. ",
        "company_entity_id": 189,
        "company_ticker": "LPCN",
        "company_name": "Lipocine Inc.",
        "company_price": "3.9600",
        "company_change": 0.35,
        "company_percent_change": 9.7,
        "company_optionable": 0,
        "company_number_of_shares": 5315830,
        "price_change_sparkline": [
            [
                3.9,
                1706677200
            ],
            [
                3.98,
                1706763600
            ],
            [
                3.94,
                1706850000
            ],
            [
                3.93,
                1707109200
            ],
            [
                4.09,
                1707195600
            ],
            [
                3.93,
                1707282000
            ],
            [
                4.01,
                1707368400
            ],
            [
                3.97,
                1707454800
            ],
            [
                4,
                1707714000
            ],
            [
                3.98,
                1707800400
            ],
            [
                4.09,
                1707886800
            ],
            [
                4.01,
                1707973200
            ],
            [
                4.01,
                1708059600
            ],
            [
                4,
                1708405200
            ],
            [
                3.95,
                1708491600
            ],
            [
                3.9,
                1708578000
            ],
            [
                3.81,
                1708664400
            ],
            [
                3.86,
                1708923600
            ],
            [
                3.86,
                1709010000
            ],
            [
                3.88,
                1709096400
            ],
            [
                3.81,
                1709182800
            ],
            [
                3.83,
                1709269200
            ],
            [
                3.65,
                1709528400
            ],
            [
                3.64,
                1709614800
            ],
            [
                3.58,
                1709701200
            ],
            [
                3.63,
                1709787600
            ],
            [
                3.61,
                1709874000
            ],
            [
                3.61,
                1710129600
            ],
            [
                3.96,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6655,
        "drug_name": "Cabenuva (cabotegravir, rilpivirine)",
        "clinical_trial_id": "NCT03497676",
        "has_trial_insight_page": 0,
        "indication": "HIV for adolescents 12 years and older",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/74605",
        "note": "Approved March 29, 2022.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6655,
        "drug_name": "Cabenuva (cabotegravir, rilpivirine)",
        "clinical_trial_id": "NCT03497676",
        "has_trial_insight_page": 0,
        "indication": "HIV for adolescents 12 years and older",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/74605",
        "note": "Approved March 29, 2022.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5185,
        "drug_name": "YESCARTA",
        "clinical_trial_id": "NCT03391466",
        "has_trial_insight_page": 0,
        "indication": "Refractory diffuse large B-cell lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GILD\/news\/75149",
        "note": "Approved April 1, 2022. ",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4581,
        "drug_name": "IGALMI (dexmedetomidine)",
        "clinical_trial_id": "NCT04268303",
        "has_trial_insight_page": 0,
        "indication": "Agitation associated with schizophrenia and bipolar disorders",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-06",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BTAI\/news\/75537",
        "note": "Approval announced April 6, 2022. ",
        "company_entity_id": 533,
        "company_ticker": "BTAI",
        "company_name": "BioXcel Therapeutics Inc.",
        "company_price": "2.7700",
        "company_change": -0.13,
        "company_percent_change": -4.48,
        "company_optionable": 1,
        "company_number_of_shares": 29272671,
        "price_change_sparkline": [
            [
                3.22,
                1706677200
            ],
            [
                3.18,
                1706763600
            ],
            [
                3.06,
                1706850000
            ],
            [
                3.71,
                1707109200
            ],
            [
                4.04,
                1707195600
            ],
            [
                3.78,
                1707282000
            ],
            [
                3.75,
                1707368400
            ],
            [
                2.11,
                1707454800
            ],
            [
                1.95,
                1707714000
            ],
            [
                2.46,
                1707800400
            ],
            [
                3.1,
                1707886800
            ],
            [
                3.59,
                1707973200
            ],
            [
                3.51,
                1708059600
            ],
            [
                3.51,
                1708405200
            ],
            [
                3.15,
                1708491600
            ],
            [
                3.17,
                1708578000
            ],
            [
                3.07,
                1708664400
            ],
            [
                3.1,
                1708923600
            ],
            [
                3.32,
                1709010000
            ],
            [
                3.27,
                1709096400
            ],
            [
                3.18,
                1709182800
            ],
            [
                3.21,
                1709269200
            ],
            [
                3.12,
                1709528400
            ],
            [
                3.02,
                1709614800
            ],
            [
                2.96,
                1709701200
            ],
            [
                3.04,
                1709787600
            ],
            [
                3.12,
                1709874000
            ],
            [
                2.9,
                1710129600
            ],
            [
                2.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9172,
        "drug_name": "Vijoice (alpelisib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "PIK3CA-Related Overgrowth Spectrum (PROS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-06",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2022\/04\/06\/2417163\/0\/en\/FDA-approves-Novartis-Vijoice-alpelisib-as-first-and-only-treatment-for-select-patients-with-PIK3CA-Related-Overgrowth-Spectrum-PROS.html",
        "note": "Approval announced April 6, 2022. ",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9187,
        "drug_name": "Cysteine Hydrochloride Injection - (Bioequivalent of Elcys)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Nutritional requirements for patients with liver disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-11",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ETON\/news\/76076",
        "note": "Approved April 11, 2022. ",
        "company_entity_id": 611,
        "company_ticker": "ETON",
        "company_name": "Eton Pharmaceuticals Inc.",
        "company_price": "4.4000",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.51,
        "company_optionable": 1,
        "company_number_of_shares": 25658396,
        "price_change_sparkline": [
            [
                4.67,
                1706677200
            ],
            [
                4.6,
                1706763600
            ],
            [
                4.49,
                1706850000
            ],
            [
                4.58,
                1707109200
            ],
            [
                4.72,
                1707195600
            ],
            [
                4.58,
                1707282000
            ],
            [
                4.41,
                1707368400
            ],
            [
                4.41,
                1707454800
            ],
            [
                4.41,
                1707714000
            ],
            [
                4.42,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.59,
                1707973200
            ],
            [
                4.4,
                1708059600
            ],
            [
                4.36,
                1708405200
            ],
            [
                4.45,
                1708491600
            ],
            [
                4.47,
                1708578000
            ],
            [
                4.47,
                1708664400
            ],
            [
                4.47,
                1708923600
            ],
            [
                4.49,
                1709010000
            ],
            [
                4.48,
                1709096400
            ],
            [
                4.45,
                1709182800
            ],
            [
                4.46,
                1709269200
            ],
            [
                4.47,
                1709528400
            ],
            [
                4.38,
                1709614800
            ],
            [
                4.33,
                1709701200
            ],
            [
                4.49,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.56,
                1710129600
            ],
            [
                4.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6327,
        "drug_name": "OPDIVO (Nivolumab) and YERVOY\u00a0(ipilimumab) - (CheckMate 816)",
        "clinical_trial_id": "NCT02998528",
        "has_trial_insight_page": 1,
        "indication": "Non-Small Cell Lung Cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-11",
        "link": "https:\/\/news.bms.com\/news\/details\/2022\/Neoadjuvant-Opdivo-nivolumab-with-Chemotherapy-Significantly-Improves-Event-Free-Survival-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial\/default.aspx",
        "note": "Approved April 11, 2022.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9199,
        "drug_name": "ALYMSYS (bevacizumab-maly)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Avastin biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AMRX\/news\/76497",
        "note": "Approved April 13, 2022.",
        "company_entity_id": 543,
        "company_ticker": "AMRX",
        "company_name": "Amneal Pharmaceuticals Inc.",
        "company_price": "5.3100",
        "company_change": -0.06999999999999995,
        "company_percent_change": -1.3,
        "company_optionable": 1,
        "company_number_of_shares": 306544199,
        "price_change_sparkline": [
            [
                5.35,
                1706677200
            ],
            [
                5.51,
                1706763600
            ],
            [
                5.52,
                1706850000
            ],
            [
                5.52,
                1707109200
            ],
            [
                5.6,
                1707195600
            ],
            [
                5.36,
                1707282000
            ],
            [
                5.46,
                1707368400
            ],
            [
                5.57,
                1707454800
            ],
            [
                5.85,
                1707714000
            ],
            [
                5.6,
                1707800400
            ],
            [
                5.82,
                1707886800
            ],
            [
                5.89,
                1707973200
            ],
            [
                5.9,
                1708059600
            ],
            [
                5.78,
                1708405200
            ],
            [
                5.73,
                1708491600
            ],
            [
                5.69,
                1708578000
            ],
            [
                5.8,
                1708664400
            ],
            [
                5.82,
                1708923600
            ],
            [
                5.71,
                1709010000
            ],
            [
                5.52,
                1709096400
            ],
            [
                5.52,
                1709182800
            ],
            [
                5.47,
                1709269200
            ],
            [
                5.4,
                1709528400
            ],
            [
                5.34,
                1709614800
            ],
            [
                5.31,
                1709701200
            ],
            [
                5.31,
                1709787600
            ],
            [
                5.39,
                1709874000
            ],
            [
                5.38,
                1710129600
            ],
            [
                5.31,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3326,
        "drug_name": "Camzyos (mavacamten)",
        "clinical_trial_id": "NCT03470545",
        "has_trial_insight_page": 0,
        "indication": "Hypertrophic cardiomyopathy (HCM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-28",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BMY\/news\/78076",
        "note": "Approved April 28, 2022. ",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3326,
        "drug_name": "Camzyos (mavacamten)",
        "clinical_trial_id": "NCT03470545",
        "has_trial_insight_page": 0,
        "indication": "Hypertrophic cardiomyopathy (HCM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-28",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BMY\/news\/78076",
        "note": "Approved April 28, 2022. ",
        "company_entity_id": 1022,
        "company_ticker": "LIAN",
        "company_name": "LianBio",
        "company_price": "4.9500",
        "company_change": 0.03,
        "company_percent_change": 0.61,
        "company_optionable": 0,
        "company_number_of_shares": 108062638,
        "price_change_sparkline": [
            [
                4.11,
                1706677200
            ],
            [
                4.18,
                1706763600
            ],
            [
                4.13,
                1706850000
            ],
            [
                4.12,
                1707109200
            ],
            [
                4.17,
                1707195600
            ],
            [
                4.1,
                1707282000
            ],
            [
                4.09,
                1707368400
            ],
            [
                4.14,
                1707454800
            ],
            [
                4.04,
                1707714000
            ],
            [
                4.8,
                1707800400
            ],
            [
                4.76,
                1707886800
            ],
            [
                4.78,
                1707973200
            ],
            [
                4.77,
                1708059600
            ],
            [
                4.79,
                1708405200
            ],
            [
                4.79,
                1708491600
            ],
            [
                4.79,
                1708578000
            ],
            [
                4.79,
                1708664400
            ],
            [
                4.81,
                1708923600
            ],
            [
                4.815,
                1709010000
            ],
            [
                4.82,
                1709096400
            ],
            [
                4.84,
                1709182800
            ],
            [
                4.88,
                1709269200
            ],
            [
                4.89,
                1709528400
            ],
            [
                4.92,
                1709614800
            ],
            [
                4.94,
                1709701200
            ],
            [
                4.9,
                1709787600
            ],
            [
                4.93,
                1709874000
            ],
            [
                4.92,
                1710129600
            ],
            [
                4.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9171,
        "drug_name": "ULTOMIRIS (ravulizumab-cwvz)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-28",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/77906",
        "note": "Approved April 28, 2022. ",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6991,
        "drug_name": "RINVOQ (upadacitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Active Ankylosing Spondylitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-04-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ABBV\/news\/78175",
        "note": "Approved April 29, 2022. ",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5686,
        "drug_name": "ENHERTU (trastuzumab deruxtecan)",
        "clinical_trial_id": "NCT03529110",
        "has_trial_insight_page": 0,
        "indication": "Second line HER2+ breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-05",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/78933",
        "note": "Approved May 5, 2022. ",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7002,
        "drug_name": "OLUMIANT (baricitinib)",
        "clinical_trial_id": "NCT04401579",
        "has_trial_insight_page": 0,
        "indication": "COVID-19",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-11",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/LLY\/news\/79845",
        "note": "FDA approval on May 11, 2022.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7400,
        "drug_name": "Mounjaro (tirzepatide)",
        "clinical_trial_id": "NCT03730662",
        "has_trial_insight_page": 0,
        "indication": "Type 2 Diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/LLY\/news\/80406",
        "note": "Approved May 13, 2022. ",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6104,
        "drug_name": "TPOXX (tecovirimat) - (IV)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Smallpox",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-19",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SIGA\/news\/81119",
        "note": "Approved May 19, 2022.",
        "company_entity_id": 526,
        "company_ticker": "SIGA",
        "company_name": "SIGA Technologies Inc.",
        "company_price": "5.3200",
        "company_change": 0.43,
        "company_percent_change": 8.79,
        "company_optionable": 1,
        "company_number_of_shares": 71091616,
        "price_change_sparkline": [
            [
                4.88,
                1706677200
            ],
            [
                4.82,
                1706763600
            ],
            [
                4.66,
                1706850000
            ],
            [
                4.51,
                1707109200
            ],
            [
                4.63,
                1707195600
            ],
            [
                4.55,
                1707282000
            ],
            [
                4.64,
                1707368400
            ],
            [
                4.9,
                1707454800
            ],
            [
                5.09,
                1707714000
            ],
            [
                4.82,
                1707800400
            ],
            [
                5.01,
                1707886800
            ],
            [
                5.15,
                1707973200
            ],
            [
                5.15,
                1708059600
            ],
            [
                5.07,
                1708405200
            ],
            [
                5.19,
                1708491600
            ],
            [
                5.14,
                1708578000
            ],
            [
                5.32,
                1708664400
            ],
            [
                5.22,
                1708923600
            ],
            [
                5.37,
                1709010000
            ],
            [
                5.33,
                1709096400
            ],
            [
                5.21,
                1709182800
            ],
            [
                5.21,
                1709269200
            ],
            [
                5.09,
                1709528400
            ],
            [
                4.96,
                1709614800
            ],
            [
                5.02,
                1709701200
            ],
            [
                4.99,
                1709787600
            ],
            [
                4.86,
                1709874000
            ],
            [
                4.89,
                1710129600
            ],
            [
                5.32,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2804,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "NCT03633617",
        "has_trial_insight_page": 0,
        "indication": "Eosinophilic esophagitis (EoE)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SNY\/news\/81323",
        "note": "Approved May 20, 2022. ",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2804,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "NCT03633617",
        "has_trial_insight_page": 0,
        "indication": "Eosinophilic esophagitis (EoE)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SNY\/news\/81323",
        "note": "Approved May 20, 2022. ",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7700,
        "drug_name": "TYVASO (treprostinil) DPI",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/UTHR\/news\/81539",
        "note": "Approved May 24, 2022.",
        "company_entity_id": 300,
        "company_ticker": "UTHR",
        "company_name": "United Therapeutics Corporation",
        "company_price": "246.8700",
        "company_change": -2.64,
        "company_percent_change": -1.06,
        "company_optionable": 1,
        "company_number_of_shares": 47058545,
        "price_change_sparkline": [
            [
                214.78,
                1706677200
            ],
            [
                215.97,
                1706763600
            ],
            [
                213.41,
                1706850000
            ],
            [
                212.76,
                1707109200
            ],
            [
                214.95,
                1707195600
            ],
            [
                210.76,
                1707282000
            ],
            [
                211.74,
                1707368400
            ],
            [
                212.34,
                1707454800
            ],
            [
                216.25,
                1707714000
            ],
            [
                213.75,
                1707800400
            ],
            [
                214.43,
                1707886800
            ],
            [
                214.54,
                1707973200
            ],
            [
                214.73,
                1708059600
            ],
            [
                214.16,
                1708405200
            ],
            [
                219.18,
                1708491600
            ],
            [
                217.6,
                1708578000
            ],
            [
                227.03,
                1708664400
            ],
            [
                223.58,
                1708923600
            ],
            [
                226.75,
                1709010000
            ],
            [
                227.28,
                1709096400
            ],
            [
                225.64,
                1709182800
            ],
            [
                231.92,
                1709269200
            ],
            [
                228.74,
                1709528400
            ],
            [
                229.81,
                1709614800
            ],
            [
                236.97,
                1709701200
            ],
            [
                239.96,
                1709787600
            ],
            [
                243.05,
                1709874000
            ],
            [
                249.51,
                1710129600
            ],
            [
                246.87,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7700,
        "drug_name": "TYVASO (treprostinil) DPI",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/UTHR\/news\/81539",
        "note": "Approved May 24, 2022.",
        "company_entity_id": 199,
        "company_ticker": "MNKD",
        "company_name": "MannKind Corporation",
        "company_price": "4.4500",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.4699999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 270418215,
        "price_change_sparkline": [
            [
                3.34,
                1706677200
            ],
            [
                3.41,
                1706763600
            ],
            [
                3.28,
                1706850000
            ],
            [
                3.25,
                1707109200
            ],
            [
                3.46,
                1707195600
            ],
            [
                3.43,
                1707282000
            ],
            [
                3.43,
                1707368400
            ],
            [
                3.51,
                1707454800
            ],
            [
                3.67,
                1707714000
            ],
            [
                3.4,
                1707800400
            ],
            [
                3.6,
                1707886800
            ],
            [
                3.71,
                1707973200
            ],
            [
                3.65,
                1708059600
            ],
            [
                3.6,
                1708405200
            ],
            [
                3.6,
                1708491600
            ],
            [
                3.59,
                1708578000
            ],
            [
                3.55,
                1708664400
            ],
            [
                3.58,
                1708923600
            ],
            [
                3.78,
                1709010000
            ],
            [
                3.92,
                1709096400
            ],
            [
                4.11,
                1709182800
            ],
            [
                4.5,
                1709269200
            ],
            [
                4.65,
                1709528400
            ],
            [
                4.75,
                1709614800
            ],
            [
                4.8,
                1709701200
            ],
            [
                5.15,
                1709787600
            ],
            [
                5.27,
                1709874000
            ],
            [
                4.61,
                1710129600
            ],
            [
                4.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9413,
        "drug_name": "Regadenoson (Lexiscan bioequivalent)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Radionuclide myocardial perfusion imaging (MPI)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AMPH\/news\/81540",
        "note": "Approved May 24, 2022. ",
        "company_entity_id": 363,
        "company_ticker": "AMPH",
        "company_name": "Amphastar Pharmaceuticals Inc.",
        "company_price": "44.1500",
        "company_change": 0.34,
        "company_percent_change": 0.78,
        "company_optionable": 1,
        "company_number_of_shares": 48095862,
        "price_change_sparkline": [
            [
                53.36,
                1706677200
            ],
            [
                53.49,
                1706763600
            ],
            [
                52.8,
                1706850000
            ],
            [
                52.35,
                1707109200
            ],
            [
                52.49,
                1707195600
            ],
            [
                52.96,
                1707282000
            ],
            [
                54.6,
                1707368400
            ],
            [
                55.61,
                1707454800
            ],
            [
                56.02,
                1707714000
            ],
            [
                54.75,
                1707800400
            ],
            [
                54.93,
                1707886800
            ],
            [
                55.51,
                1707973200
            ],
            [
                54.06,
                1708059600
            ],
            [
                52.45,
                1708405200
            ],
            [
                51.25,
                1708491600
            ],
            [
                51.91,
                1708578000
            ],
            [
                53.41,
                1708664400
            ],
            [
                55.09,
                1708923600
            ],
            [
                55.44,
                1709010000
            ],
            [
                54.74,
                1709096400
            ],
            [
                46.57,
                1709182800
            ],
            [
                46.22,
                1709269200
            ],
            [
                46.68,
                1709528400
            ],
            [
                47.33,
                1709614800
            ],
            [
                46.31,
                1709701200
            ],
            [
                46.76,
                1709787600
            ],
            [
                45.67,
                1709874000
            ],
            [
                43.81,
                1710129600
            ],
            [
                44.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9415,
        "drug_name": "VTAMA (tapinarof)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Plaque psoriasis ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-05-24",
        "link": "https:\/\/investor.roivant.com\/news-releases\/news-release-details\/fda-approves-dermavants-vtamar-tapinarof-cream-1-treatment",
        "note": "Approved May 24, 2022. ",
        "company_entity_id": 1485,
        "company_ticker": "ROIV",
        "company_name": "Roivant Sciences Ltd.",
        "company_price": "10.2900",
        "company_change": -0.15000000000000002,
        "company_percent_change": -1.44,
        "company_optionable": 1,
        "company_number_of_shares": 805846006,
        "price_change_sparkline": [
            [
                10,
                1706677200
            ],
            [
                10.05,
                1706763600
            ],
            [
                9.89,
                1706850000
            ],
            [
                10.02,
                1707109200
            ],
            [
                10.3,
                1707195600
            ],
            [
                10.39,
                1707282000
            ],
            [
                10.57,
                1707368400
            ],
            [
                10.81,
                1707454800
            ],
            [
                10.87,
                1707714000
            ],
            [
                10.8,
                1707800400
            ],
            [
                11.32,
                1707886800
            ],
            [
                11.45,
                1707973200
            ],
            [
                11.59,
                1708059600
            ],
            [
                11.54,
                1708405200
            ],
            [
                11.54,
                1708491600
            ],
            [
                11.36,
                1708578000
            ],
            [
                11.6,
                1708664400
            ],
            [
                11.7,
                1708923600
            ],
            [
                11.8,
                1709010000
            ],
            [
                11.71,
                1709096400
            ],
            [
                11.44,
                1709182800
            ],
            [
                11.77,
                1709269200
            ],
            [
                11.48,
                1709528400
            ],
            [
                11.6,
                1709614800
            ],
            [
                11.57,
                1709701200
            ],
            [
                11.15,
                1709787600
            ],
            [
                10.68,
                1709874000
            ],
            [
                10.44,
                1710129600
            ],
            [
                10.29,
                1710216000
            ]
        ],
        "statuses": []
    }
]